Abstract 2381
Background
There has been an increasing concern about the changing incidence patterns of some types of cancers including age at diagnosis. While there is at least some evidence that some cancers currently occur at age earlier than that expected based on historical data, we still lack evidence about age trends in most types of cancers. This study aims to explore current age distributions for different types of malignancies in the United States based on data from SEER.
Methods
Data were obtained using SEER*Stat version 8.3.5, where (SEER 18 Regs Nov 2017 Submission) database was used as the data source. Only cases diagnosed between 1996-2015 with malignant behavior, known age, and microscopic confirmation were included. Data were exported using the case listing session and were analyzed using SPSS version 21.
Results
Median age at diagnosis was significantly higher in the period between 2006-2015 than in the period 1996-2005 for most types of cancers. GIT malignancies and CML, however, showed an exception with a significantly younger median age of diagnosis. The table shows age distribution as well as median age for some common types of cancers including comparison between cases in the 1996-2005 and 2006-2015 time periods.Table: 1582P
| Median Age (in years) | Number and Percentage of Cases in Different Age Groups (1996-2015) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| < 18 years | 18-35 years | ears | > 55 years | ||||||||
| 1996-2015 | 1996-2005 | 2006-2015 | N | % | N | % | N | % | N | % | |
| CML | 65 | 66 * | 64 | 476 | 1.9% | 2310 | 9.0% | 6033 | 23.6% | 16781 | 65.6% |
| NHL | 67 | 66 | 67 | 4135 | 1.4% | 13792 | 4.7% | 61630 | 21.1% | 212389 | 72.7% |
| HD | 38 | 37 | 39 * | 3501 | 8.6% | 15123 | 37.3% | 11242 | 27.8% | 10638 | 26.3% |
| Lung Cancer | 70 | 70 | 70 | 116 | .0% | 2571 | .3% | 100142 | 12.0% | 731999 | 87.7% |
| Breast Cancer | 61 | 61 | 62 * | 11 | .0% | 23824 | 2.3% | 340441 | 33.4% | 655907 | 64.3% |
| Bladder Cancer | 72 | 72 | 72 | 75 | .0% | 1705 | .6% | 30047 | 10.1% | 264547 | 89.3% |
| Gonadal Cancer | 63 | 63 | 63 | 97 | .1% | 2887 | 3.2% | 26422 | 29.1% | 61458 | 67.6% |
| Cervical and Uterine Cancer | 60 | 59 | 60 * | 22 | .0% | 13937 | 5.7% | 77435 | 31.9% | 151283 | 62.3% |
| Colorectal Cancer | 69 | 71 * | 67 | 338 | .0% | 10166 | 1.5% | 133171 | 19.2% | 550771 | 79.3% |
| Stomach Cancer | 70 | 71 * | 69 | 36 | .0% | 1952 | 1.8% | 18304 | 17.3% | 85274 | 80.8% |
| Liver Cancer | 64 | 65 * | 63 | 208 | .2% | 1100 | 1.0% | 23862 | 22.0% | 83175 | 76.8% |
| Pancreatic Cancer | 70 | 71 * | 69 | 58 | .0% | 998 | .6% | 22136 | 14.1% | 134330 | 85.3% |
Significantly higher median age.
Conclusions
Except for GIT malignancies and CML, cancer is still being diagnosed at higher median age. With few exceptions, patients who are over 55 years old are still constituting the vast majority of cases.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract